Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States

AIDS

Volumn 27, Issue 15, 2013, Pages 2413-2423

  Murphy, Kerry ^a   Hoover, Donald R ^b   Shi, Qiuhu ^c   Cohen, Mardge ^d,e   Gandhi, Monica ^f   Golub, Elizabeth T ^g   Gustafson, Deborah R ^h,i   Pearce, Celeste Leigh ^j   Young, Mary ^k   Anastos, Kathryn ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Department of Medicine   (United States)

^e RUSH UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

AIDS; HAART; HIV; Race; Survival; Women

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ILLICIT DRUG; INTEGRASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; AMERICAN INDIAN; ARTICLE; ASIAN; CAUCASIAN; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CENTER FOR EPIDEMIOLOGY STUDIES DEPRESSION SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PACIFIC ISLANDER; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RACE; SCORING SYSTEM; SELF REPORT; TRANSFUSION; UNITED STATES; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84884493068     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432537.92958.73     Document Type: Article

References (74)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. WHO Library Cataloguing-in- Publication Data; 2010.
2. WHOReport Women and Health: today's evidence tomorrow's agenda. WHO Library Cataloguing-in-Publication Data; 2009.
3. Hall HI, An Q, Hutchinson A, Sansom S. Estimating the lifetime risk of a diagnosis of the HIV infection in 33 states, 2004-2005. J Acquir Immune Defic Syndr 2008; 49:294-297.
4. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al., for the HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
5. Xu JQ, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. National vital statistics reports. Vol 58. Hyattsville, MD: National Center for Health Statistics; 2010.
6. Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med 2012; 172:1591-1598.
7. Cunningham W. HIV racial disparities time to close the gaps comment on 'the influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007'. Arch Intern Med 2012; 172:1599-1600.
8. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35:1541-1548.
9. Silverberg M, Leyden W, Quesenberry C, Horberg M. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. JGen InternMed 2009; 24:1065-1072.
10. Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis 2012; 55:1242-1251.
11. Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009; 199:991-998.
12. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, et al., and the IDCRP HIV Working Group. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52:574-580.
13. Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr 2007; 44:411-416.
14. McGinnis KA, Fine MJ, Sharma RK, Skanderson M, Wagner JH, Rodrigues-Barradas MC, et al. Understanding racial disparities in HIV using data from the Veterans Aging Cohort 3-Site Study and VA Administrative Data. Am J Public Health 2003; 93:1728-1733.
15. Evans C, et al. Meta-analysis of differences in viral suppression by race in clinical trials. ICAAC 2012[Abstract H-881].
16. Giordano TP, Bartsch G, Zhang Y, Tedaldi E, Absalon J, Mannheimer S, et al. Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) Trial. AIDS Patient Care STDs 2010; 24:287-295.
17. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96-103.
18. Cohen MH, Cook JA, Grey D, Young M, Hanau LH, Tien P, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health 2004; 94:1147-1151.
19. Thrasher AD, Earp JA, Golin CE, Zimmer CR. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-Infected patients. J Acquir Immune Defic Syndr 2008; 49:84-93.
20. Mannheimer S, Friedland G, Matts J, Child C, Chesney M, for the Terry Beirn Community Programs for Clinical Research on AIDS. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115-1121.
21. Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, et al., for the Women's Interagency HIV Study Collaborative Group. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39:537-544.
22. Barkan S, Melnick S, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
23. DHHS/Henry J. Kaiser Family Foundation Panel on clinical practices for the treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; November 3, 2008 revision. http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf.
24. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measur 1977; 1:385-401.
25. Berkman LF, Berkman CS, Kasl S, Freeman DH Jr, Leo L, Ostfeld AM, et al. Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol 1986; 124:372-388.
26. Hertzog C, Vanalstine J, Usala PD, Hultsch DF, Dixon R. Measurement properties of the Center for Epidemiologic Studies Depression scale (CES-D) in older populations. Psychol Assess 1990; 2:64-72.
27. Nguyen HT, Kitner-Triolo M, Evans MK, Zonderman AB. Factorial invariance of the CES-D in low socioeconomic status African Americans compared with a nationally representative sample. Psychiatry Res 2004; 126:177-187.
28. Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113: 91-98.
29. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51:399-406.
30. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
31. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guidelines for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993; 14:702-715.
32. Al-Harthi L, Voris J, Du W, Nowicki M, Frederick T, Landay A, Kovacs A. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006; 193: 1202-1210.
33. Klein JP, Moeschberger ML. Survival analysis techniques for censored and truncated data. 2nd ed. New York, NY: Springer-Verlag; 2003.
34. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York, NY: Oxford University Press; 1994.
35. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
36. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619-630.
37. Telenti A, Zanger UM. Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 2008; 48:.
38. Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol 2008; 16:620-627.
39. International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2011; 330:1551-1557.
40. Kuniholm MH, Gao X, Xue X, Kovacs A, Anastos K, Marti D, et al. Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy. J Virol 2011; 85:10826-10833.
41. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008; 14:413-420.
42. Brumme ZL, Brumme CJ, Chui C, Mo T, Wynhoven B, Woods CK, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007; 195:1694-1704.
43. Rauch A, Nolan D, Furrer H, McKinnon E, John M, Mallal S, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008; 46:1921-1925.
44. Mehlotra RK, Cheruvu VK, Blood Zikursh MJ, Benish RL, Lederman MM, Salata RA, et al. Chemokine (C-C Motif) receptor 5: 2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis 2011; 204:291-298.
45. Ameyaw MM, Regateiro F, Li T, Tariq M, Mobarek A, Thornton N, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
46. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
47. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-850.
48. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44:499-523.
49. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical significance. Clin Pharmacol Ther 2004; 75:13-33.
50. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
51. Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin Drug Deliv 2006; 3:23-35.
52. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-1942.
53. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17:1696-1698.
54. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral response. AIDS 2003; 17:201-208.
55. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenzcontaining regimens for initial HIV therapy results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-554.
56. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Shackman BR, Meyer WA 3rd, et al., for the ACTG A5095 Study Team. Threevs. four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized control trial. JAMA 2006; 296:769-781.
57. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group Study. J Infect Dis 2010; 202:717-722.
58. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401-407.
59. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199:872-880.
60. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type-1 infected individuals with cytochrome P450 2B6 M6 and M26. Clin Infect Dis 2007; 45:1230-1237.
61. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al., on behalf of the German Competence Network for HIV/AIDS. Impact of the CYP2B6 983T >C polymorphism on nonnucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-918.
62. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, et al., on behalf of participants in the workshop 'Pharmocogenomics: a path towards personalized HIV care'. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011; 12:277-285.
63. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A Single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012; 206:1453-1461.
64. Pettit JW, Lewinsohn PM, Seeley JR, Roberts RE, Hibbard JH, Hurtado AV. Association between the Center for Epidemiologic Studies Depression Scale (CES-D) and mortality in a community sample: an artifact of the somatic complaints factor? Int J Clin Health Psychol 2008; 8:382-397.
65. Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIVseropositive women. J Acquir Immune Defic Syndr 2002; 30: 401-409.
66. jCook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133-1140.
67. Cook JA, Grey D, Burke-Miller J, Cohen MH, Anastos K, Gandhi M, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multisite cohort of HIV-positive women. AIDS Care 2006; 18:93-100.
68. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011; 52:1267-1275.
69. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair samples strongly predict virologic responses to HIV treatment. AIDS 2009; 23:471-478.
70. Hessol NA, Schwarcz S, Ameli N, Oliver G, Greenblatt RM. Accuracy of self-reports of acquired immunodeficiency syndrome and acquired immunodeficiency syndrome: related conditions in women. Am J Epidemiol 2001; 153:1128-1133.
71. Hernando V, Sobrino-Vegas P, Carmen Burriel M, Berenguer J, Navarro G, Santos I, et al. Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS 2012; 26:1829-1834.
72. Lifson AR, and the INSIGHT Cause of Death Writing Group. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9:177-185.
73. Selik RM, Anderson RN, McKenna MT, Rosenberg HM. Increase in deaths caused by HIV infection due to changes in rules for selecting underlying cause of death. J AIDS 2003; 32:62-69.
74. Grigg B, Brooks RG, Lieb S, Grigg M. Coding changes and apparent HIV-AIDS mortality trends in Florida, 1999. JAMA 2001; 286:1839.